Microfluidics Firm Arradial Secures $3M in Additional Series A Financing | GenomeWeb

NEW YORK, April 16 - Arradial, a spin-off of Alexion Pharmaceuticals that develops microfluidic-based microarray technology, today said it has secured $3 million in additional Series A financing from Oxford Bioscience Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.